Marker Therapeutics, Inc. (MRKR)
1.40
-0.06
(-4.11%)
USD |
NASDAQ |
Jun 09, 13:18
Marker Therapeutics SG&A Expense (Quarterly) : 1.230M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 41.01M |
| Vericel Corp. | 49.23M |
| ADMA Biologics, Inc. | 27.80M |
| Gyre Therapeutics, Inc. | 21.36M |
| Savara, Inc. | 15.57M |